Ro KhannaBuy
REGN Common Stock · Transaction Jul 7, 2026 · Filed Aug 7, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · REGN
-1.33% · -$10.71 · Vol 488.3K
Market closed · last close 4:00 PM ET · price as of 18:46:05 ET
Regeneron Pharmaceuticals Inc
Biotechnology
$797.00
Veridion Score
BETAHIGH CONF · 6/6 factorsFri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET · REGN
MethodologyREGN
Regeneron Pharmaceuticals Inc
Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
69/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Fri Aug 28 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is REGN moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Regeneron Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
1991
Employees
15K
Country
US
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$809.40
Day high
$809.40
Day low
$789.08
Previous close
$807.71
52W high
$840.84
-5.21% from high
52W low
$555.51
85% of range
Market cap
$81.8B
P/E
17.55×
EPS
$45.41
Beta
0.39
Shares out
103M
Volume
488.3K
0.63× rel vol
Avg volume
773.6K
VWAP
$793.99
Price history computed in-house
1W
-4.44%
1M
+4.51%
3M
+32.69%
1Y
+37.25%
YTD
+3.26%
SMA 50 $716.62 · above
SMA 200 $728.69 · above
52W position 85%
REGN overview
SEC industry peers
REGN peers
Related filings and maps
Public disclosures
Congress activity in REGN
Official filing ↗
Ro KhannaBuy
REGN Common Stock · Transaction Jun 16, 2026 · Filed Jul 6, 2026 · $1,001 to $15,000
Ro KhannaSell
REGN Common Stock · Transaction Jun 2, 2026 · Filed Jul 6, 2026 · $1,001 to $15,000
REGN · Transaction May 15, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
Regeneron Pharmaceuticals, Inc. - Common Stock · Transaction May 15, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
Federal contracts
REGN contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for REGN in this window.
Lobbying spend
REGN lobbying filings, year to date.
Registered lobbying filings matched to Regeneron Pharmaceuticals Inc.
$2.1M
Refresh interval: 12hSource: LDA disclosure filings
Health IssuesHealth Issues
Medicare/Medicaid
Copyright/Patent/Trademark
Trade (domestic/foreign)
Taxation/Internal Revenue CodeTaxation/Internal Revenue Code
Health Issues
Medicare/Medicaid
Copyright/Patent/Trademark
Trade (domestic/foreign)
Filing
$640.0K
REGENERON PHARMACEUTICALS INC
REGENERON PHARMACEUTICALS, INC
Apr 20, 2026
Filing
$630.0K
REGENERON PHARMACEUTICALS INC
REGENERON PHARMACEUTICALS, INC
Jul 20, 2026
Filing
$610.0K
REGENERON PHARMACEUTICALS INC
REGENERON PHARMACEUTICALS, INC
Jan 20, 2026
Analyst ratings
Sovereign unlock shows live analyst consensus for REGN.
Options
Sovereign unlock shows live options positioning for REGN.